Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NERATINIB MALEATE

NERATINIB MALEATE

Standard Dose
40MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview NERATINIB MALEATE is listed in Drugs@FDA under application 216236 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NERATINIB MALEATE Form and strength TABLET;ORAL - 40MG Sponsor SANDOZ INC Submission history Latest submission status date: 2022-07-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview NERATINIB MALEATE is listed in Drugs@FDA under application 216236 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NERATINIB MALEATE Form and strength TABLET;ORAL - 40MG Sponsor SANDOZ INC Submission history Latest submission status date: 2022-07-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.